EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

B cells and antibodies in refractory immune thrombocytopenia

Anaïs Roeser iD, Alan H Lazarus, Matthieu Mahévas iD

British Journal of Haematology · 2023-10 · 203 (1) · 43-53

DOI: 10.1111/bjh.18773 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2023-04. Verfasst von Anaïs Roeser und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, ATIP-Avenir TeamAI2B, Paris, France. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by pathogenic autoantibodies secreted by plasma cells (PCs) in many patients. In refractory ITP patients, the persistence of splenic and bone marrow autoreactive long‐lived PCs (LLPCs) may explain primary failure of rituximab and splenectomy respectively. The reactivation of autoreactive memory B cells generating new autoreactive PCs contributes to relapses after initial response to rituximab. Emerging strategies targeting B cells and PCs aim to prevent the settlement of splenic LLPCs with the combination of anti‐BAFF and rituximab, to deplete autoreactive PCs with anti‐CD38 antibodies, and to induce deeper B‐cell depletion in tissues with novel anti‐CD20 monoclonal antibodies and anti‐CD19 therapies. Alternative strategies, focused on controlling autoantibody mediated effects, have also been developed, including SYK and BTK inhibitors, complement inhibitors, FcRn blockers and inhibitors of platelet desialylation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicHumansRituximabB-LymphocytesPlasma CellsAutoantibodies

Stichwörter der Autor:innen

B cellsITPantibodiesimmunethrombocytopenia

Substanzen

RituximabAutoantibodies

Autor:innen und Institutionen

  • Institut Necker Enfants Malades (INEM), INSERM U1151/CNRS UMS 8253, ATIP-Avenir TeamAI2B, Paris, France.
  • Service de Médecine Interne, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.
  • Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
  • Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Innovation and Portfolio Management, Canadian Blood Services, Ottawa, Ontario, Canada.

ORCID-Profile: Anaïs Roeser, Matthieu Mahévas

Zitieren

APA

Roeser, A., Lazarus, A. H., & Mahévas, M. (2023). B cells and antibodies in refractory immune thrombocytopenia. British Journal of Haematology, 203(1), 43-53. https://doi.org/10.1111/bjh.18773

Vancouver

Roeser A, Lazarus AH, Mahévas M. B cells and antibodies in refractory immune thrombocytopenia. British Journal of Haematology. 2023;203(1):43-53. doi:10.1111/bjh.18773

BibTeX
@article{Roeser2023,
  author = {Roeser, Anaïs and Lazarus, Alan H and Mahévas, Matthieu},
  title = {B cells and antibodies in refractory immune thrombocytopenia},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {203},
  number = {1},
  pages = {43--53},
  doi = {10.1111/bjh.18773}
}
Kostenlos starten →